CD274 and neoplasm: In addition to the limitations associated with physically obtaining tissue samples, the performance of tissue biomarkers in predicting ICI resistance is known to be imperfect—with some low PD-L1 expressing and low TMB tumours still benefiting with immunotherapy treatment (9, 149).